Comparative Pharmacology
Head-to-head clinical analysis: WEGOVY HD versus YEZTUGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: WEGOVY HD versus YEZTUGO.
WEGOVY HD vs YEZTUGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
WEGOVY (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist that increases insulin secretion, decreases glucagon secretion, delays gastric emptying, and promotes satiety.
Yeztugo (tugofinitib) is a selective inhibitor of fibroblast growth factor receptor (FGFR) 1-4. It binds to the ATP-binding pocket of FGFR kinases, blocking downstream signaling pathways (RAS-MAPK, PI3K-AKT, STAT) involved in cell proliferation and survival.
Subcutaneous injection once weekly. Initiate at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg weekly for 4 weeks, then 1 mg weekly for 4 weeks, then 1.7 mg weekly for 4 weeks, then maintain at 2.4 mg weekly.
YEZTUGO is not an approved drug. No standard dosing available.
None Documented
None Documented
Terminal elimination half-life approximately 165 hours (≈7 days), supporting once-weekly dosing.
12-15 hours in healthy adults; prolonged to 24-30 hours in moderate hepatic impairment.
Primarily renal elimination of intact peptide; ~47% excreted unchanged in urine, remainder via fecal/biliary routes (≈38%).
Primarily renal (>90% unchanged) with 5-10% biliary/fecal elimination.
Category C
Category C
GLP-1 Receptor Agonist
GLP-1 Receptor Agonist